Zanidatamab Zovodotin is a monoclonal antibody conjugated commercialized by Zymeworks, with a leading Phase I program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 5 clinical trials, of which 1 is ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zanidatamab Zovodotin’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Zanidatamab Zovodotin is expected to reach an annual total of $48 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Zanidatamab Zovodotin Overview

Zanidatamab Zovodotin is under development for the treatment of HER-2 positive breast cancer, brain metastases, endometrial cancer, gastroesophageal adenocarcinoma, gynecologic cancers, metastatic breast cancer, non-small cell lung cancer, anal cancer, and colorectal cancer. It is being administered through intravenous route. It comprises Azymetric biparatopic anti-HER2 antibody conjugated to proprietary cytotoxic payload (auristatin) via a cleavable linker. The drug candidate is an bi-specific antibody-drug conjugate (biparatopic antibody) targeting tumor cells expressing ECD4 and ECD2 epitopes of HER2. It is developed based on Azymetric and Zymelink technology platforms. These technologies enables the production of ADCs with target affinity, effector function and increase in circulation half life. ZW49 delivers a novel auristatin (cell-killing compound) to tumor cells by taking advantage of the enhanced antibody-HER2 internalization of zanidatamab.

Zymeworks Overview

Zymeworks is a clinical-stage biopharmaceutical company that discovers, develops and commercializes biotherapeutics for the treatment of cancer, autoimmune and inflammatory diseases. The company’s lead product candidates are Zanidatamab for the treatment of biliary tract cancers, breast cancer, gastroesophageal adenocarcinomas and colorectal cancer, Zanidatamab Zovodotin for HER2-expressing cancers. Its other preclinical pipeline includes ZW191 – TOPO1i antibody-drug conjugate for ovarian and gynecological cancers and ZW171 for solid tumors. Zymeworks technology platform comprises Azymetric, Zymelink, Efect and Protect. It operates in the US and Canada. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
The company reported revenues of (US Dollars) US$412.5 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$26.7 million in FY2021. The operating profit of the company was US$130.5 million in FY2022, compared to an operating loss of US$215.6 million in FY2021. The net profit of the company was US$124.3 million in FY2022, compared to a net loss of US$211.8 million in FY2021. The company reported revenues of US$16.5 million for the third quarter ended September 2023, compared to a revenue of US$7 million the previous quarter.

For a complete picture of Zanidatamab Zovodotin’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.